
By Iacob Pastina, Independent Researcher
Semaglutide Before and After: Weight Loss Results by Month
Clinical trials show 15–17% body weight loss with semaglutide over 68 weeks. Here's what to expect month by month, backed by data from the STEP trials.
Summarize this article with
People taking semaglutide 2.4mg (Wegovy) lost an average of 15–17% of their body weight over 68 weeks in the landmark [STEP clinical trials](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183) — that's roughly 35 lbs for someone starting at 230 lbs. Weight loss follows a predictable curve: modest in months 1–2 as the dose ramps up, accelerating through months 3–6, and plateauing around months 12–16. One-third of participants lost 20% or more of their body weight. Here's a detailed timeline of what to expect, backed by published trial data. See providers ranked by lowest semaglutide price, or take our match quiz to find the best fit.
Semaglutide Weight Loss Timeline: Month by Month
Semaglutide is prescribed as a once-weekly injection with a gradual dose increase over 16–20 weeks. Weight loss tracks closely with the dose escalation — here's what the clinical data shows:
| Timeframe | Dose | Average Weight Lost | What to Expect |
|---|---|---|---|
| Month 1–2 | 0.25mg → 0.5mg | 2–4% (~5–9 lbs) | Appetite suppression begins. Some nausea as your body adjusts. Most people notice reduced food cravings within the first 2 weeks. |
| Month 3–4 | 1.0mg | 5–8% (~12–18 lbs) | Weight loss accelerates. Nausea typically subsides. Clothing fits differently. Most noticeable visual changes begin. |
| Month 5–6 | 1.7mg → 2.4mg | 8–12% (~18–28 lbs) | Reaching maintenance dose. Significant visible changes. Energy levels often improve as excess weight decreases. |
| Month 7–9 | 2.4mg (maintenance) | 12–15% (~28–35 lbs) | Approaching peak weight loss. Body composition changes become dramatic. Blood markers (A1C, triglycerides) often normalize. |
| Month 10–12 | 2.4mg (maintenance) | 14–16% (~32–37 lbs) | Weight loss slows as you approach your new set point. Focus shifts to maintenance and habit consolidation. |
| Month 12–16+ | 2.4mg (maintenance) | 15–17% (~35–39 lbs) | Plateau phase. Weight stabilizes. The STEP-1 trial showed weight remains stable through week 68 with continued use. |
STEP Trial Results: The Clinical Evidence
The STEP (Semaglutide Treatment Effect in People with Obesity) trials are the largest and most rigorous studies of semaglutide for weight loss. Here's what each trial found:
| Trial | Participants | Duration | Average Weight Loss | Key Finding |
|---|---|---|---|---|
| STEP 1 | 1,961 adults with obesity | 68 weeks | 14.9% (vs 2.4% placebo) | One-third lost 20%+ body weight |
| STEP 2 | 1,210 adults with T2 diabetes + obesity | 68 weeks | 9.6% (vs 3.4% placebo) | Effective even with type 2 diabetes, though less than non-diabetic patients |
| STEP 3 | 611 adults with obesity + behavioral therapy | 68 weeks | 16.0% (vs 5.7% placebo) | Adding behavioral intervention increased results to 16% |
| STEP 4 | 902 adults (withdrawal study) | 68 weeks | 17.4% lost during treatment | Participants regained 2/3 of weight within 1 year of stopping |
| STEP 5 | 304 adults with obesity | 2 years | 15.2% (vs 2.6% placebo) | Weight loss maintained over 2 years of continued treatment |
The most important finding: the STEP 4 withdrawal study showed that patients regained approximately two-thirds of their lost weight within one year of stopping semaglutide. This confirms that semaglutide works as ongoing treatment, not a short-term fix.
What Affects Your Results?
Clinical trial averages don't tell the whole story. Several factors influence how much weight you'll lose on semaglutide:
- •Starting weight — People with higher starting BMI tend to lose a larger absolute amount of weight, though percentage loss is similar across weight ranges.
- •Dose reached — The 2.4mg maintenance dose produced the best results in trials. Some patients can't tolerate the full dose and stay at 1.0mg or 1.7mg, which produces less weight loss (approximately 10–12%).
- •Diet and exercise — The STEP 3 trial added intensive behavioral therapy (diet counseling + exercise) and achieved 16% weight loss vs 14.9% in STEP 1 with medication alone.
- •Type 2 diabetes — Patients with T2 diabetes lost less weight (9.6% in STEP 2 vs 14.9% in STEP 1), likely due to insulin resistance and diabetes medications that promote weight gain.
- •Genetics and metabolism — About 10–15% of trial participants were classified as 'non-responders' who lost less than 5% body weight despite full dosing. There's no reliable way to predict this in advance.
- •Consistency — Missing doses reduces efficacy. The weekly injection schedule must be maintained consistently for optimal results.
Semaglutide vs Tirzepatide: Which Produces Better Results?
If you're comparing options, tirzepatide (Zepbound/Mounjaro) produces significantly more weight loss than semaglutide in head-to-head trials:
| Metric | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Average weight loss | 15–17% (STEP trials, 68 weeks) | 20–22.5% (SURMOUNT trials, 72 weeks) |
| Head-to-head (SURMOUNT-5) | 13.7% | 20.2% (p<0.001) |
| Patients losing 20%+ | ~33% | ~57% |
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Monthly cost (compounded) | $99–$199/mo | $149–$300/mo |
Tirzepatide costs $50–$150/month more but produces roughly 50% more weight loss. Read our full semaglutide vs tirzepatide comparison or see tirzepatide cost breakdown for pricing details.
What Happens When You Stop Semaglutide?
The STEP 4 trial directly studied what happens after discontinuation — and the results are sobering. After achieving 17.4% weight loss over 20 weeks, participants who switched to placebo regained approximately two-thirds of their lost weight over the following year. Those who continued semaglutide maintained their weight loss.
This doesn't mean semaglutide is a failure — it means obesity is a chronic condition that requires ongoing treatment, similar to blood pressure medication. The American Medical Association and the Obesity Medicine Association both classify obesity as a chronic disease requiring long-term management.
How to Maximize Your Results
- •Follow the dose escalation schedule — Don't rush to the maintenance dose. The gradual increase (0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg over 16–20 weeks) reduces side effects and improves long-term adherence.
- •Prioritize protein intake — GLP-1 medications can cause muscle loss alongside fat loss. Aim for 0.7–1.0g protein per pound of body weight daily to preserve lean mass. The STEP 3 trial included dietary guidance and saw better outcomes.
- •Add resistance training — Weight-bearing exercise helps preserve muscle during rapid weight loss. Even 2–3 sessions per week makes a measurable difference in body composition.
- •Stay hydrated — Semaglutide slows gastric emptying, which can cause constipation. Drinking 80+ oz of water daily helps manage this common side effect.
- •Track your progress monthly, not weekly — Weight fluctuates daily due to water retention, food timing, and hormonal cycles. Monthly measurements give a more accurate picture of your trajectory.
- •Communicate with your provider — If nausea persists beyond the first month or weight loss stalls, your provider can adjust timing, suggest anti-nausea strategies, or modify your dose. Our dosing timeline tool shows what a typical titration schedule looks like.
Getting Started: Cheapest Semaglutide Options
If you're ready to start semaglutide, here are the most affordable ways to access it in 2026:
- •Cheapest compounded semaglutide: Sesame Care starts at $99/mo, Enhance MD at $115/mo, and Strut Health at $149/mo (oral tablets). Shed offers $149/mo with the fastest delivery in the industry. See all providers ranked by price.
- •Mid-range with more support: Sprout Health ($250/mo) includes a dedicated care coordinator and published outcomes data. Eden Health ($249/mo) includes quarterly lab panels and obesity medicine physicians.
- •Brand-name with insurance: If your insurance covers Wegovy, apply for the Novo Nordisk savings card for $25/month copays.
- •Medicare: Starting July 2026, Part D covers Wegovy at $50/month through the GLP-1 Bridge Demonstration. See our Medicare GLP-1 coverage guide.
- •Not sure which provider? Take our 7-question match quiz to find the best provider for your budget, insurance status, and preferences.
Frequently Asked Questions
How much weight will I lose on semaglutide in 3 months? Based on the STEP trials, most patients lose 5–8% of their body weight in the first 3 months (roughly 12–18 lbs for a 230-lb person). You'll still be ramping up to the maintenance dose during this period, so weight loss accelerates after month 3.
Do semaglutide results last? As long as you continue treatment, yes. The STEP 5 trial showed sustained weight loss over 2 full years of treatment. However, stopping semaglutide typically leads to weight regain — the STEP 4 withdrawal study showed approximately two-thirds of lost weight returned within one year of stopping.
Is semaglutide worth it? For most patients with a BMI of 30+ (or 27+ with comorbidities), semaglutide produces significant, clinically meaningful weight loss with manageable side effects. The STEP trials showed improvements in blood pressure, blood sugar, triglycerides, and waist circumference alongside weight loss. The main consideration is cost and the commitment to long-term use.
What are the most common side effects? Nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) were the most common in STEP 1. Most side effects occur during dose escalation and resolve within 4–8 weeks. Read our GLP-1 side effects management guide for detailed strategies.
Sources
- STEP 1: Semaglutide 2.4mg for Weight Management — New England Journal of Medicine, 2021
- STEP 2: Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes00213-0/fulltext) — The Lancet, 2021
- STEP 3: Semaglutide with Intensive Behavioral Therapy — JAMA, 2021
- STEP 4: Continued Treatment vs Withdrawal — JAMA, 2022
- STEP 5: Two-Year Treatment with Semaglutide — Nature Medicine, 2022
- SURMOUNT-5: Tirzepatide vs Semaglutide Head-to-Head — New England Journal of Medicine, 2025
- AMA Resolution on Obesity as a Chronic Disease — American Medical Association
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication. Information is current as of the publication date but may change.
Affiliate Disclosure: Some links in this article are affiliate links. We may earn a commission if you sign up through our links, at no extra cost to you.